1. Leucht S, Bauer S, Siafis S, Hamza T, Wu H, Schneider-Thoma J, Salanti G, Davis JM. Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis. JAMA Psychiatry. 2021 Aug 18:e212130. doi: 10.1001/jamapsychiatry.2021.2130. Epub ahead of print. PMID: 34406325; PMCID: PMC8374744.
2. Barak Y, Aizenberg D. Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment. BMC Psychiatry. 2012;12:108. Published 2012 Aug 10. doi:10.1186/1471-244X-12-108
3. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638-645.
4. S. M. Stahl and N. Muntner, Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press, 2019.
5. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Can J Psychiatry. 2017 Sep;62(9):604-616. doi: 10.1177/0706743717720448. Epub 2017 Jul 13. PMID: 28703015; PMCID: PMC5593252.
6. Leucht S, Samara M, Heres S, et al. Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method. Schizophrenia Bulletin, 2014. Volume 40, Issue 2. Pages 314–326. https://doi.org/10.1093/schbul/sbu001
7. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull. 2016 Jul;42 Suppl 1(Suppl 1):S90-4. doi: 10.1093/schbul/sbv167. PMID: 27460622; PMCID: PMC4960429.
8. Taniguchi M, Hatano M, Kamei H, Inagaki R, Yamada S. Factors That Affect Continuation of Antipsychotic Long-Acting Injections. Biol Pharm Bull. 2019;42(7):1098-1101. doi: 10.1248/bpb.b19-00001. PMID: 31257286.
9. Heidi Taipale and others, Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia, Schizophrenia Bulletin, Volume 48, Issue 4, July 2022, Pages 774–784, https://doi.org/10.1093/schbul/sbac039
10. Jan P A M Bogers and others, Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis, Schizophrenia Bulletin Open, Volume 1, Issue 1, January 2020, sgaa002, https://doi.org/10.1093/schizbullopen/sgaa002
11. Begemann, M.J.H., Thompson, I.A., Veling, W. et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials 21, 147 (2020). https://doi.org/10.1186/s13063-019-3822-5
12. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, Gastaldon C, Papola D, Purgato M, Nosari G, Del Giovane C, Correll CU, Barbui C. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022 Jun;21(2):295-307. doi: 10.1002/wps.20972. PMID: 35524620; PMCID: PMC9077618.